Valuation: Alector, Inc.

Market Cap 18Cr 16Cr 15Cr 14Cr 26Cr 1.73TCr 26Cr 175.37Cr 69Cr 850.87Cr 68Cr 67Cr 2.95TCr P/E 2026 *
-1.91x
P/E 2027 * -2.55x
Enterprise Value -6.56Cr -5.74Cr -5.29Cr -4.9Cr -9.29Cr -626.24Cr -9.45Cr -63Cr -25Cr -307.52Cr -25Cr -24Cr -1.07TCr EV / Sales 2026 *
-9.57x
EV / Sales 2027 * -6.33x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-10.66%
1 week-20.63%
Current month-18.66%
1 month+0.31%
3 months-31.88%
6 months-12.10%
Current year+4.81%
1 week 1.6
Extreme 1.6
2.06
1 month 1.41
Extreme 1.41
2.14
Current year 1.41
Extreme 1.41
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
39.22
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
17/06Free

Director

38,150 0.0344%
17/06Free

Director

38,150 0.0344%
17/06Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
-10.66%-20.63%-0.91%-73.46% 18Cr
-0.25%-4.33%+63.74%+126.05% 5.7TCr
+4.91%-0.19%+73.70%+92.14% 5.36TCr
+1.48%+5.97%+22.59%+495.47% 2.56TCr
-0.59%-4.68%-16.82%-12.99% 2.35TCr
+2.43%+1.06%+47.70%-0.11% 1.94TCr
-0.85%+2.30%+37.07%-25.19% 1.81TCr
-6.84%+2.18%+203.03%+348.11% 1.65TCr
+8.74%+3.51%+53.81% - 1.41TCr
+1.76%+2.24%+29.57%+195.70% 1.44TCr
Average +0.01%-1.29%+51.35%+127.30% 2.42TCr
Weighted average by Cap. +1.40%-0.33%+57.30%+142.74%

Financials

2026 *2027 *
Net sales 68.57L 59.98L 55.31L 51.18L 97.14L 65Cr 98.77L 6.62Cr 2.6Cr 32Cr 2.57Cr 2.52Cr 111.33Cr 2.29Cr 2Cr 1.85Cr 1.71Cr 3.24Cr 218.41Cr 3.3Cr 22Cr 8.67Cr 107.25Cr 8.59Cr 8.4Cr 371.51Cr
Net income -9.41Cr -8.23Cr -7.59Cr -7.02Cr -13Cr -898.3Cr -14Cr -91Cr -36Cr -441.12Cr -35Cr -35Cr -1.53TCr -9.66Cr -8.45Cr -7.79Cr -7.21Cr -14Cr -922.21Cr -14Cr -93Cr -37Cr -452.87Cr -36Cr -35Cr -1.57TCr
Net Debt -25Cr -22Cr -20Cr -18Cr -35Cr -2.36TCr -36Cr -238.75Cr -94Cr -1.16TCr -93Cr -91Cr -4.01TCr -33Cr -29Cr -26Cr -24Cr -46Cr -3.12TCr -47Cr -315.3Cr -123.6Cr -1.53TCr -122.52Cr -119.87Cr -5.3TCr
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
09/26/09 $1.635 -10.66% 5,89,285
08/26/08 $1.830 -5.18% 6,43,891
07/26/07 $1.930 -0.52% 4,16,164
06/26/06 $1.940 -5.83% 5,88,496
02/26/02 $2.060 +2.49% 3,94,059
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.635USD
Average target price
3.100USD
Spread / Average Target
+89.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock